On November 16, 2026, Galectin Therapeutics Inc. announced its financial results for the six months ending September 30, 2026, along with a business update. This announcement is significant as it reflects the company's ongoing commitment to developing therapeutics that target galectin proteins, particularly in the treatment of liver diseases.

Galectin Therapeutics, based in Norcross, Georgia, is a pharmaceutical company focused on developing innovative treatments for serious diseases. The company operates under the SIC code 2834, which pertains to Pharmaceutical Preparations, and its stock is traded on the Nasdaq under the ticker symbol GALT. Recent filings include a Form 8-K filed on November 16, 2026, and a Form 10-Q also filed on the same date.

In its latest filing, Galectin Therapeutics reported that it had successfully submitted its registrational Phase 3 protocol to the FDA after aligning on key elements of the trial design. CEO Joel Lewis expressed optimism about the company’s data being presented at major liver conferences, stating, "We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations." The company aims to advance its belapectin program, which targets galectin-3, a protein involved in metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.

This update may impact various stakeholders, including investors, healthcare professionals, and patients seeking new treatment options for liver diseases. The pharmaceutical industry, particularly in the area of liver therapeutics, may also feel the competitive pressure as Galectin continues to make strides in its clinical programs.

Looking ahead, Galectin Therapeutics is expected to provide further updates at its Annual Stockholders’ Meeting scheduled for December 3, 2026. This meeting will likely shed more light on the company’s future direction and ongoing projects.